ReviewHealthcare (Basel, Switzerland)2026
Primary Immunodeficiency Disorders and Inborn Errors of Immunity in Saudi Arabia: Current Evidence on Epidemiology, Clinical Impact, and Healthcare System Challenges.
Review in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term inborn errors of immunity (IEI) is now widely used to describe many conditions historically known as primary immunodeficiency disorders (PIDs), comprising a heterogeneous group of rare diseases that affect immune system development and/or function and increase the risk of inflammation, infection, immune dysregulation, and malignancy. In Saudi Arabia, the clinical impact of PID/IEI is particularly significant owing to the high consanguinity rates, delayed diagnosis, variable access to specialized immunology services, and limited national records. This narrative review summarizes the available literature on PID/IEI in Saudi Arabia, emphasizing the epidemiology, clinical impact, diagnostic delay, treatment access, healthcare system challenges, and evidence gaps. Relevant literature was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar, supplemented by regional and grey literature, where applicable. The available evidence suggests that PID/IEI remains underrecognized in Saudi Arabia, with published data largely derived from single-center studies, selected cohorts, and hospital-based registries. The current literature highlights important recurring themes, including the significance of consanguinity, the high reported incidence of severe combined immunodeficiency (SCID) in selected studies, timely diagnosis, registry data, and the value of strengthening screening and referral pathways. However, evidence regarding treatment costs, long-term morbidity, quality of life, and regional disparities in access to care remains scarce. Establishing national PID/IEI registries, expanding newborn screening, enhancing primary-care physicians' awareness, improving genetic diagnostic capacity, and developing clearer referral pathways are important priorities to improve early diagnosis, patient outcomes, and healthcare system preparedness in Saudi Arabia, prioritized by healthcare authorities under Saudi Vision 2030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.